Other research analysts have also issued research reports about the stock. LADENBURG THALM/SH SH reaffirmed a positive rating and set a $239.00 target price (up previously from $133.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, October 16th. National Securities lowered shares of Reata Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, November 13th. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, November 27th. Stifel Nicolaus reaffirmed a buy rating and set a $305.00 price objective (up previously from $210.00) on shares of Reata Pharmaceuticals in a research report on Thursday, November 14th. Finally, Citigroup lifted their target price on shares of Reata Pharmaceuticals from $241.00 to $328.00 and gave the company a buy rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Reata Pharmaceuticals presently has an average rating of Buy and a consensus target price of $255.63.
Shares of Reata Pharmaceuticals stock opened at $202.65 on Tuesday. The firm has a market cap of $5.93 billion, a PE ratio of -70.61 and a beta of 2.64. Reata Pharmaceuticals has a 52 week low of $47.50 and a 52 week high of $222.33. The business’s fifty day simple moving average is $195.85 and its 200-day simple moving average is $113.19.
In other news, CAO Elaine Castellanos sold 4,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $200.00, for a total transaction of $800,000.00. Following the sale, the chief accounting officer now owns 19,146 shares of the company’s stock, valued at $3,829,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James Warren Huff sold 63,000 shares of the stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $86.61, for a total transaction of $5,456,430.00. Following the sale, the chief executive officer now directly owns 164,157 shares in the company, valued at approximately $14,217,637.77. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 103,000 shares of company stock valued at $11,049,910. 34.40% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Resources Investment Advisors LLC. acquired a new position in Reata Pharmaceuticals during the 2nd quarter worth $25,000. Meadow Creek Investment Management LLC raised its position in Reata Pharmaceuticals by 71.4% in the 2nd quarter. Meadow Creek Investment Management LLC now owns 336 shares of the company’s stock valued at $32,000 after purchasing an additional 140 shares in the last quarter. Lindbrook Capital LLC acquired a new stake in Reata Pharmaceuticals in the 3rd quarter valued at about $32,000. Glen Harbor Capital Management LLC boosted its stake in shares of Reata Pharmaceuticals by 71.4% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 408 shares of the company’s stock valued at $39,000 after buying an additional 170 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Reata Pharmaceuticals by 1,603.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock valued at $44,000 after buying an additional 513 shares during the period. Institutional investors and hedge funds own 60.04% of the company’s stock.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Featured Article: Rule of 72
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.